Evidence map›Paper›PMID 37452388›Full record

ArticleJournal of pharmaceutical policy and practice2023

Prevalence, types and disclosure of complementary and alternative medicine (CAM) use among chronic kidney disease (CKD) patients in Saudi Arabia.

Ghada Ben Salah, Maryam Farooqui, Mohammed Salem Alshammari, Abir Elghazali, Lamyaa Kassem, Nada Ibrahim, Imen Ben Abdelmalek, Muhammad Kamran Rasheed

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ghada Ben SalahDepartment of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah, 52571, Saudi Arabia.
Maryam FarooquiDepartment of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Buraydah, 52571, Saudi Arabia. m.farooqui@qu.edu.sa.ORCID http://orcid.org/0000-0002-3380-5855
Mohammed Salem AlshammariDepartment of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Buraydah, 52571, Saudi Arabia.
Abir ElghazaliDepartment of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Buraydah, 52571, Saudi Arabia.
Lamyaa KassemDepartment of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Buraydah, 52571, Saudi Arabia.
Nada IbrahimDepartment of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Buraydah, 52571, Saudi Arabia.
Imen Ben AbdelmalekDepartment of Biology, College of Science, Qassim University, Buraydah, 52571, Saudi Arabia.
Muhammad Kamran RasheedDepartment of Pharmacy Practice, College of Pharmacy, Qassim University, Buraydah, 52571, Saudi Arabia.
Qassim University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite the paucity of scientific evidence, CAM is widely used for the prevention and treatment of illness among patients with chronic kidney disease, including end-stage renal disease and kidney transplant recipients. It is evident that the irrational use of CAM among CKD patients and its non-disclosure to healthcare providers could lead to adverse drug events. Hence, the current study was conducted to evaluate the prevalence, types, and non-disclosure of CAM use among CKD patients and kidney transplant recipients in Saudi Arabia.

methodsA cross-sectional study was conducted on 170 CKD patients (121 with stages 3 and 4, two with stage 5 and on hemodialysis, and 47 kidney transplant recipients). Face-to-face questionnaire-based interviews were conducted employing a convenience sampling technique. The study outcomes were the prevalence of CAM, types of CAM use, monthly expenditure on CAM, the source of information about CAM, and CAM disclosure to healthcare providers. A p-value of < 0.05 was considered significant.

resultsThe study found that out of 170, 60 (35.3%) CKD patients use CAM. The most used CAM was Acacia gum (49, 81.6%) followed by spiritual therapies (34, 56.6%). Female CKD patients had higher use of CAM compared to the male gender (p = 0.015). The monthly expenditures that most users (47, 78.3%) spent on CAM were less than 50 Saudi Riyals (SR). The study results also showed that 55% of CKD patients did not report their CAM use to their physicians. Furthermore, 46.6% of CAM users discontinue their use of CAM after observing no benefit.

conclusionThis study reported relatively high use of CAM among CKD patients in Saudi Arabia. The study found that most CKD patients use Acacia gum and spiritual therapies and do not disclose the use of CAM to healthcare professionals, which could lead to adverse drug events. Therefore, the study recommends that healthcare providers should inquire and provide evidence-based counselling about the use of CAM to CKD patients to prevent any adverse drug event or unwanted effect on the renal function of the patients.

Indexed as

Adverse eventChronic diseaseChronic kidney diseaseComplementary and alternative medicinesCross-sectional studiesHealth surveysPublic healthSaudi ArabiaTreatment

Identifiers

PMID37452388
PMCPMC10347759
OpenAlexW4384339806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.